Metraipolis › archive › dc_16495cd76a6a

A TP53-Pathway-Based Prognostic Signature for Radiotherapy and Functional Validation of TP53I3 in Non-Small-Cell Lung Cancer — Europe PMC PMID:41681932

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41681932
DOI
10.3390/cancers18030457
License (as archived)
solo-consultazione
Archived
2026-11-06T09:49:43.339Z
SHA-256 of the archived text
bdcf6230baea640cb954541b71313af7177f7c94478ddb8be9b56d7716947f5f
Stable URL of this page
https://metraipolis.com/documento/dc_16495cd76a6a

How to cite

A TP53-Pathway-Based Prognostic Signature for Radiotherapy and Functional Validation of TP53I3 in Non-Small-Cell Lung Cancer — Europe PMC PMID:41681932 — Europe PMC (en), https://europepmc.org/article/MED/41681932 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_16495cd76a6a (Metraipolis archive dc_16495cd76a6a, sha256 bdcf6230baea640cb954541b71313af7177f7c94478ddb8be9b56d7716947f5f)
BibTeX
@misc{dc16495cd76a6a,
  title = {A TP53-Pathway-Based Prognostic Signature for Radiotherapy and Functional Validation of TP53I3 in Non-Small-Cell Lung Cancer — Europe PMC PMID:41681932},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41681932},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_16495cd76a6a; sha256 bdcf6230baea640cb954541b71313af7177f7c94478ddb8be9b56d7716947f5f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41681932. Agents can read the archived copy with the MCP tool read_document.